Core Viewpoint - Anhui Wanbang Pharmaceutical Technology Co., Ltd. held its 19th meeting of the second board of directors, where several key resolutions were passed regarding the revision of the company's articles of association and governance structures, as well as the nomination of candidates for the third board of directors [1][2][3][4][5]. Group 1: Board Meeting Details - The board meeting was convened on August 4, 2025, with all six directors present, complying with relevant laws and the company's articles of association [1]. - The meeting's agenda included the revision of the company's articles of association to enhance governance and internal control [1][2]. Group 2: Resolutions Passed - The board approved the proposal to revise the articles of association, which will be submitted to the shareholders' meeting for a vote requiring a two-thirds majority [2]. - A series of governance system revisions were also approved, all requiring shareholder approval [2][3]. - The board nominated two candidates, Tao Chunlei and Xu Xinluo, for the third board of directors, with the term starting upon shareholder approval [3][4]. - Two independent director candidates, Zhang Hongbin and Zhuo Min, were nominated for the third board, pending review by the Shenzhen Stock Exchange [4]. - The board agreed to reappoint Rongcheng Accounting Firm for the 2025 financial audit, subject to shareholder approval [5]. - A second extraordinary shareholders' meeting is scheduled for August 21, 2025, to discuss the approved proposals [5].
万邦医药: 第二届董事会第十九次会议决议公告